SATELLOS BIOSCIENCE ANNOUNCES OTCQB LISTING IN THE UNITED STATES

TORONTO, October 6, 2022 – Satellos Bioscience Inc. (TSXV: MSCL OTCQB: MSCLF) (“Satellos” or the
“Corporation”), a drug discovery company aimed at developing therapeutics that regenerate muscle as
a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce
that its common shares have commenced trading on the OTCQB Venture Market (“OTCQB”) under the
symbol “MSCLF”. Shares in Satellos will continue to trade on the TSXV under the symbol MSCL.
“Listing on the OTCQB is a testament to the foundational success we’ve experienced to date,” said
Satellos Co-Founder and CEO, Frank Gleeson. “The retail and institutional investment communities in
the United States will now have easier access to playing a part in the advancements we’re making to
improve the lives of individuals suffering from a wide range of muscular dystrophies. We are thrilled to
be growing our investor base while we enter this important phase for the company.”
The OTCQB is the premiere marketplace for early stage and developing companies that are committed
to providing a high-quality trading and information experience for their U.S. investors. To qualify for
OTCQB, companies must meet high financial standards, follow best practice corporate governance, and
demonstrate compliance with applicable securities laws. The OTCQB quality standards provide a strong
baseline of transparency as well as the technology and regulation to improve the information and
trading experience for investors. The OTCQB is recognized by the Securities and Exchange Commission
(SEC) as an established public market providing public information for analysis and value of securities.
Investors can find financial disclosure and Real-Time Level 2 quotes for the Corporation
at www.otcmarkets.com.
About Satellos Bioscience Inc.
Satellos is a biotechnology company dedicated to developing life-changing medicines to treat
degenerative muscle conditions. Our scientists discovered what we believe to be a previously
unrecognized root cause of skeletal muscle degeneration. One which has the potential to transform how
muscle disorders are treated. Our scientific founder, Dr. Michael Rudnicki, is a thought leader who
discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. He
has shown how defects in a process known as stem cell "polarity", which controls how muscle stem cells
divide to create muscle progenitor cells, lead to a failure of muscle regeneration in Duchenne and
potentially other muscle disorders. As a result of this ongoing inability to produce sufficient numbers of
new muscle cells, the muscles of people living with Duchenne are unable to keep up with and repair the
continuous and accumulating damage their muscles experience. Satellos' lead program is focused on
developing an oral therapeutic drug (i.e., a pill) intended to correct muscle stem cell polarity and restore
the body's innate muscle repair and regeneration process. We believe our unique therapeutic approach
represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new
hope to patients. To expand our programs to other degenerative muscle conditions or disorders,
Satellos has created a proprietary discovery platform, MyoReGenX™, which we utilize to identify disease
situations where deficits in muscle stem cell polarity and regeneration occur and are amenable to

therapeutic treatment. For more information about or to discuss potential collaborations with Satellos
concerning our discovery platform and therapeutic candidates or our subsidiary Amphotericin B
Technologies Inc., please contact Ryan Mitchell, Ph.D., Director – Business Development at
rmitchell@satellos.com or visit Satellos.com.
CONTACT:
Christina Cameron, Communications
Satellos Bioscience Inc.
ccameron@satellos.com
647.660.1780
Notice on forward-looking statements:
This press release includes forward-looking information or forward-looking statements within the
meaning of applicable securities laws regarding Satellos and its business, which may include, but are not
limited to, statements regarding the anticipated benefits from appointing Dr. Lambert as CTO; the
general benefits of modulating stem cell polarity; its prospective impact on Duchenne patients and
muscle regeneration generally; and Satellos' technologies and drug development plans. All statements
that are, or information which is, not historical facts, including without limitation, statements regarding
future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or
beliefs of future performance, are "forward-looking information or statements". Often but not always,
forward-looking information or statements can be identified by the use of words such as "shall",
"intends", "anticipate", "believe", "plan", "expect", "intend", "estimate" "anticipate"  or any variations
(including negative variations) of such words and phrases, or state that certain actions, events or results
"may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such
statements are based on the current expectations and views of future events of the management of the
Company. They are based on assumptions and subject to risks and uncertainties. Although management
believes that the assumptions underlying these statements are reasonable, they may prove to be
incorrect. The forward-looking events and circumstances discussed in this release, may not occur and
could differ materially as a result of known and unknown risk factors and uncertainties affecting the
Company, including risks relating to the pharmaceutical and bioscience industry, general market
conditions and equity markets, economic factors and management's ability to manage and to operate
the business of the Company generally. Although Satellos has attempted to identify important factors
that could cause actual actions, events or results to differ materially from those described in forward-
looking statements, there may be other factors that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any
forward-looking statements or information. No forward-looking statement can be guaranteed. Except as
required by applicable securities laws, forward-looking statements speak only as of the date on which
they are made and Satellos does not undertake any obligation to publicly update or revise any forward-
looking statement, whether as a result of new information, future events, or otherwise.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX
Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.